CBIO Lupus Data Published By Oxford Journals
28 October 2011: CBio Limited (ASX:CBZ) is pleased to announce that its research “Recombinant chaperonin10 (XToll) suppresses cutaneous lupus and lupus nephritis in MRL-(Fas)lpr mice” is now published on the advanced access site of the Oxford Journals publication, Nephrology Dialysis Transplantation.
In CBio’s study, treatment of mice with XToll entirely prevented cutaneous lupus. XToll also significantly suppressed nephritis in the kidneys, and significantly prolonged life span. In humans, nephritis in the kidneys is a major cause of mortality and shortened life span of patients with lupus.
XToll also reduced the levels of pro-inflammatory cytokines such as IL-6 and TNF-alpha, a finding consistent with data from the company’s phase IIa rheumatoid arthritis clinical trial.
This research indicates that in addition to rheumatoid arthritis, XToll could have utility in the treatment of human lupus, either alone or as part of a drug combination therapy. It is estimated the lupus market will be worth $2.5 billion per annum by 2017.
CBio Chairman Mr Stephen Jones said the publication of this data represents another milestone for the company and is further corroboration of the strategy of the Board in its development program for XToll.
“The strategy of the Board has been to undertake projects that add the greatest value to XToll,” Mr Jones said.
“With the acceptance this week of rheumatoid arthritis data to the American College of Rheumatology Annual Scientific Meeting and now the publication of lupus data in the Oxford Journals, the Board’s strategy for the development of XToll continues to be validated,” he said.
CBio has a credible and internationally experienced Board of Directors which includes pre-eminent pharmaceutical industry figures who are experienced in taking drugs to market.
About CBio Limited
CBio is an Australian ASX listed company established in 2000. CBio’s lead product XToll is a potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis (RA) and lupus. Global sales of RA therapies exceeded US$17 billion in 2008. The global lupus market is expected to reach $2.5 billion per annum by 2017. CBio’s Board includes internationally experienced drug developers Dr Goran Ando, Vice-Chairman Novo Nordisk A/S (formerly president of R&D at Pharmacia/Pfizer and R&D director of Glaxo Group, UK); Dr Thomas Lönngren (former Executive Director of the European Medicines Agency), Dr Terje Kalland (retired Vice President Biopharmaceuticals Research Unit- Novo Nordisk); Dr Peter Corr, Founder and co-General Partner of Celtic Therapeutics (formerly Senior Vice-President for Science and Technology at Pfizer and Chairman of the Board of Governors, New York Academy of Sciences); and Professor John Funder, AO, Professor of Medicine at Monash University, Senior Fellow at Prince Henry's Institute of Medical Research (former Director of the Baker Institute, 1990-2001).
Manager Corporate Projects
T: +61 (0)449 148 448
Level 37 530 Collins Street
Melbourne VIC 3000
p: 03 9620 3333
Posted: October 2011